Bring your Semaglutide questions to the screen
A remote appointment is easier to prepare for when you know what still needs an answer.
Promise Peptides, found at mypromise.com, currently has U.S.-licensed providers prescribing compounded Semaglutide for prescription peptide therapy. Each request needs a licensed provider's review and decision on prescribing; not every applicant will qualify. U.S. patients only. Compounded medicines are not FDA-approved.
01 Start with the people in the study
You might arrive with a medicine in mind and a screenshot to explain why. Fair enough. Before the appointment, it helps to ask who was in that study and what the researchers were trying to change.
Semaglutide and tirzepatide make a good example. A bigger weight-loss result can be useful information, but it can't tell a prescriber everything about you. The reason for treatment, your health history and the exact product still matter.
Two findings worth keeping in view
Weight loss and heart health are different questions. Here is what two trials found.
| Study | People & time | Finding | What it can answer |
|---|---|---|---|
| SURMOUNT-5 | Adults with obesity, without type 2 diabetes; 72 weeks. | Average weight loss: 20.2% with tirzepatide and 13.7% with semaglutide. | A direct comparison at the highest study doses participants could tolerate. |
| SELECT | Adults aged 45 or older with established heart or blood-vessel disease, a body mass index (BMI) of at least 27, and no diabetes. | Lower combined risk of death from heart or blood-vessel disease, nonfatal heart attack or nonfatal stroke with semaglutide. | A comparison with placebo, not tirzepatide. |
The weight comparison was funded by Eli Lilly, which makes tirzepatide. It was open-label: participants and researchers knew the assigned medicine. The heart-outcome study asked a separate question.
These trials studied manufactured medicines. They do not establish the safety or effectiveness of a compounded preparation with the same ingredient name.
Neither result picks a medicine for you. Our semaglutide and tirzepatide comparison puts the findings beside the safety questions, so the biggest number doesn't get the whole conversation.
What to bring to remote review
Useful notes can be ordinary: the medicines and supplements you take, past reactions, relevant health history and pregnancy plans. Add the question that's hardest to squeeze into a form. You don't need a polished speech.
The Wegovy (semaglutide) label rules out use with a personal or family history of medullary thyroid carcinoma, a rare thyroid cancer. It also flags serious stomach problems and other health details for review. A checklist alone cannot settle whether treatment fits.
The medical boards' telemedicine model policy calls for an assessment that allows follow-up questions. It's guidance for boards, rather than one nationwide law. Our appointment notes explain what that can mean in practice.
And after the appointment?
We'd want to know who handles a new symptom and what happens if the plan is hard to tolerate. Nausea, vomiting, diarrhea and constipation appear in the Wegovy label. Persistent symptoms need a conversation, even when they're familiar side effects.
The STEP 1 follow-up study also found substantial weight regain after medicine and lifestyle support ended. That makes the longer plan worth discussing early. Our follow-up page starts there.
One more distinction belongs on the table: compounded medicines are not FDA-approved. An ingredient name and a prescription don't give a compounded preparation the approval of a manufactured medicine.